https://www.selleckchem.com/pe....ptide/gp91ds-tat.htm
Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn's disease. This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity, and efficacy of risankizumab in responders to risankizumab in the parent phase 2 study. Enrolled patients had achieved clinical response (decrease in Crohn's Disease Activity Index from baseline ≥10 without clinical remission (Crohn's Disease Activity Index 15 at Week
Like
Comment
Share
